

CURRICULUM VITAE
Mark Lawrence Hudak, M.D.

DATE OF BIRTH: January 16, 1954
Orange, New Jersey

OFFICE: Division of Neonatology
University of Florida Health Science Center/Jacksonville
653-1 West 8th Street
Jacksonville, Florida 32209
(904) 244-3508

EDUCATION:

1975	B.A., Chemistry, <u>summa cum laude</u> Amherst College Amherst, Massachusetts
1979	M.D., The Johns Hopkins University Baltimore, Maryland

TRAINING:

1979 - 1982	Intern and Resident Department of Pediatrics The Harriet Lane Service The Johns Hopkins Hospital Baltimore, Maryland
1982 - 1984	Fellow, Division of Neonatology Department of Pediatrics The Johns Hopkins Hospital Baltimore, Maryland

APPOINTMENTS:

1984 - 1985	Instructor in Pediatrics The Johns Hopkins University School of Medicine
1985 - 1990	Assistant Professor of Pediatrics The Johns Hopkins University School of Medicine
1989 - 1990	Director, Neonatal Respiratory Therapy and Blood Gas Laboratory The Johns Hopkins Hospital
1990 - 1995	Associate Professor of Pediatrics State University of New York at Buffalo Children's Hospital of Buffalo
1990 - 1995	Medical Director Newborn and Intensive Care Nurseries The Children's Hospital of Buffalo
1996 - 1998	Project Director Early Intervention Program University of Florida College of Medicine - Jacksonville
1995 - Present	Professor of Pediatrics University of Florida College of Medicine - Jacksonville
1995 - Present	Chief, Division of Neonatology Department of Pediatrics University of Florida College of Medicine – Jacksonville
1996 – 2004	Medical Director Neonatal Intensive Care Unit Wolfson Children's Hospital Jacksonville, Florida
1998 - Present	Assistant Chairman for Finance and Clinical Affairs Department of Pediatrics University of Florida College of Medicine - Jacksonville
1999 – 2004	Member, Pediatric Advisory Subcommittee, Pediatric Anti-infective Drugs Advisory Committee to the Food and Drug Administration, Rockville, Md.

2002 – Present	Chairman, Finance Committee University of Florida Jacksonville Physicians, Inc.
2003 – Present	Assistant Dean of Managed Care for the University of Florida University of Florida College of Medicine - Jacksonville
2004-Present	Assistant Medical Director Neonatal Intensive Care Unit Wolfson Children’s Hospital Jacksonville, Florida
July 04–Feb 05; Apr 06-	Interim Medical Director Pediatric Intensive Care Unit Wolfson Children’s Hospital Jacksonville, Florida
July 04–Feb 05; Nov 06-	Interim Division Chief, Critical Care Medicine Department of Pediatrics University of Florida College of Medicine - Jacksonville
2005-	Co-Leader, Shands Jacksonville/University of Florida College of Medicine - Jacksonville Medicaid Reform Task Force
2006-present	Medical Director, ECMO Program Wolfson Children’s Hospital
2006-present	Associate Medical Director PediCare Program for Title XXI and Title XIX children
2007 – present	Associate Chairman, Department of Pediatrics University of Florida College of Medicine – Jacksonville
May 07 – Jun 07	Interim Division Chief, Developmental Pediatrics Executive Director, CARD and FDLRS
Sep 07 - present	Interim Medical Director First Coast Advantage Jacksonville, Florida
Nov 07 - present	Ped-I-Care Quality and Utilization Management Committee

LICENSURE:

1990
1997

New York, 183514
Florida, ME 0075147

Revised: 11/24/2008

CERTIFICATION:

1985	Pediatrics
1985	Neonatal-Perinatal Medicine

SOCIETIES/ASSOCIATIONS/HONORS:

1975	Phi Beta Kappa
1975	Sigma Xi
1986	American Academy of Pediatrics, Fellow
1986 -1990	Committee on Fetus and Newborn, Maryland Chapter, American Academy of Pediatrics
1989	American Thoracic Society, Fellow
1997	Member, The Florida Society of Neonatologists, Inc.
1998	Subsection on Perinatal-Neonatal Medicine, American Academy of Pediatrics
1999	Subsection on Perinatal-Neonatal Medicine, American Academy of Pediatrics
1999 –2000	Secretary/Treasurer, The Florida Society of Neonatologists, Inc.
1999	Southeastern Society of Neonatologists
2000-2002	President-Elect, The Florida Society of Neonatologists, Inc.
2002-2004	President, The Florida Society of Neonatologists, Inc
2003	Researcher of the Year Award, University of Florida at Shands Jacksonville
2004-Present	Member, Committee on Drugs, American Academy of Pediatrics
2005-Present	St. Johns Riverkeeper, Inc., Member of the Board of Directors
2005-Present	St. Johns Riverkeeper, Inc., Treasurer
2006-Present	Member, National Association of Managed Care Physicians (NAMCP)
2007	Member, Society for Pediatric Research

COMMITTEES:

University of Florida at Shands Jacksonville (Formerly University Medical Center):

1996 – Present	University of Florida Health Science Center / Member, Medicare Compliance Committee
1996 - 1997	Member, Productivity-based Compensation Committee
1996 - Present	Member, Managed Care Committee
1998 - Present	Member at Large, UFJP Board of Directors
1999 - Present	Member, UFJP Finance Committee
2000 - Present	QI/UM Business Committee
2002 - Present	Chairman, UFJP Finance Committee
2002 - Present	Prospective Audit Feasibility Committee
2002 – 2004	Pediatric Clinic Move Planning Committee
2002 – Present	Physician's Compensation Plan Committee
2004 – Present	Clinical Operations Committee

University of Florida Health Science Center Jacksonville
Jacksonville, FL

GRANTS/CONTRACTS:

Recent and Active Support

- 09/26/08 – 09/25/13 National Children's Study
A study to examine the effects of environmental influences on the health and development of more than 100,000 children across the United States, following them from birth until age 21.
Sponsor: NIH(East RFP-NIH-NICHD-NCS-008-2)
Role: Lead Local Investigator For baker County; 25% effort
- 12/2008 – 12/2013 Intestinal Microecology, Inflammatory Markers and Necrotizing Enterocolitis
A study to identify intestinal high risk microbiota patterns associated with NEC, evaluate relationships between fecal microbiota to: inflammatory markers in plasma in NEC and non-NEC patients and Buccal epithelium inflammatory marker patterns in NEC and non-NEC patients, and to correlate intestinal microbiota and inflammatory marker patterns with microbes isolated ob blood culture during sepsis.
Sponsor: NIH
Role: Co-Investigator
- 01/2009 -01/2011 Fluconazole Prophylaxis for the prevention of Candidiasis in Infants <750 grams birth weight
Phase 3, randomized blinded, multi-center, placebo-controlled study of the efficacy and safety of fluconazole administration for the prevention of neonatal candidiasis in infants <750 grams birth weight.
Sponsor: NIH
Role: Local Principal Investigator
- 06/11/08 – 06/11/09 The Feeding Study in Premature Infants
Sponsor: Mead Johnson & Co.
Role: Local Co-Investigator
- 3/1/02 – 2008 Low Dose Inhaled Nitric Oxide for the Prevention & Treatment of Chronic Lung Disease in the Preterm Infant (NO/CLD Study).
Sponsor: NHLBI
Local PI: Mark L. Hudak, M.D.,
University of Florida Health Science Center at Jacksonville;
PI = Roberta A. Ballard, University of Pennsylvania
Support: \$1500.00 per patient enrolled

5/28/04-4/06 A Phase III, randomized, double-blind, multi-center clinical trial comparing the safety and efficacy of Veronate versus placebo for the prevention of nosocomial staphylococcal sepsis in premature infants (birth wt 500-1250 g). IGG-CL-006
Sponsor: Inhibitex
Local PI: Mark L. Hudak, M.D.,
University of Florida Health Science Center at Jacksonville, Florida.
Support: Up to \$5,000.00 per patient enrolled

1/3/01 – 2005 Inhaled Nitric Oxide for Preterm Infants with Severe Respiratory Failure (PINO)
Sponsor: INO Therapeutics, Inc. and NICHD Neonatal Network
Local PI: Mark L. Hudak, M.D., University of Florida Health Science Center at Jacksonville; PI = Krisa van Meurs, Stanford University
Support: \$1500.00 per patient enrolled.

Previous Support:

7/01/86 - 11/30/87 Co-Investigator, NIH PO1-NS 200020-05: Mechanisms of Regulation Of Cerebral Blood Flow in the Fetus and Newborn
15% effort.

12/01/87 -11/30/90 Co-Investigator, Project V. Cerebral Blood Flow in the Fetus and Newborn.
25% effort.
In Program Project (NIH PO1-NS 20020-05):
Mechanisms of Regulation of Cerebral Blood Flow.

2/10/89 - 6/30/90 Principal investigator, NIH RR 00052, Pediatric CRC: BPD and ROP in the Neonate: Clinical Trial of Vitamin A.
Total support: \$23,000.

7/01/89 - 6/30/90 Principal Investigator, Thomas Wilson Sanitarium:
Effect of Timing of Surfactant Treatment on Long-term Pulmonary and Neurologic Outcome in the Extremely Low Birth Weight Infant.
Total support: \$15,000.

7/01/89 - 6/30/90 Principal Investigator, American Lung Association of Maryland: Effect of Vitamin A Supplementation on Chronic Lung Disease in the Surfactant-Treated Extremely Low Birth Weight Infant: A Randomized Controlled, Double-Blind Clinical Trial.
Total support: \$12,000.

- 12/01/91 - 11/30/96 Co-Investigator, Project VI: Mechanisms and Therapy of Lung Injury in Animals Models.
5% effort.
In SCOR (NIH P50-HL36543):
Respiratory Diseases of Neonates and Children –
Program Director: Robert Notter, M.D., Ph.D.
Total direct costs (Project 6): \$650,000.
- 1/01/91 - 6/30/94 Principal Investigator, National Randomized Double-Masked Comparison Trial of Two Surfactants (Exosurf vs. Infasurf) in the Prophylaxis and Treatment of Respiratory Distress Syndrome.
Forest Laboratories and ONY, Inc.
Total support: \$2,544,890.
- 5/01/92 - 4/30/94 Principal Investigator, Women and Children's Research Foundation:
Role of surfactant proteins in the optimization of surfactant therapy for RDS.
40% effort.
Total direct costs: \$49,175.
- 2/01/93 - 8/12/02 Principal Investigator: Surfactant Comparison Trial: Long Term Neurodevelopmental Follow-up.
Forest Laboratories.
10% effort.
Total direct costs: \$1,128,773.
- 10/01/93 - 06/30/97 Principal Investigator: A Randomized Controlled Trial of the Safety and Efficacy of Two Treatment Protocols for Infasurf Administration.
Forest Laboratories and ONY, Inc.
Total direct costs: > \$566,078.

- 1/01/95 - 12/31/97 Co-Investigator, NIH 1 UIO EY09953: LIGHT-ROP.
5% effort.
Principal Investigator: James D. Reynolds, MD
Total direct costs: \$395,868.
- 01/01/95 – 5/25/00 Principal Investigator: A Randomized Double-Masked Trial of Inhaled Nitric Oxide and Infasurf in the Treatment of Infants with Parenchymal Lung Disease, Pulmonary Hypertension, and Respiratory Failure.
Forest Laboratories; ONY, Inc.; Dräger, Inc.; and Scott Medical Products.
Total support: \$450,000.
- 6/12/97 – 4/15/02 Local Principal Investigator: The Safety and Efficacy of r-h-Cu Zn SOD to prevent Bronchopulmonary Dysplasia when administered intratracheally to preterm infants with Respiratory Distress Syndrome- A Phase III Multiple Dose Study.
Winthrop-University Hospital, Mineola, NY
Support: \$3750.00 per patient enrolled.
- 7/01/97 - 6/30/98 Local Principal Investigator: A Randomized Trial of Non-tidal Oscillatory vs Tidal Ventilation in Infants with Birth Weights Between 500 and 1200 grams: A pilot study.
PI: Sherry Courtney, M.D., Cooper Hospital, New Jersey
Support = \$1,200 per patient.
- 4/01/97 – 4/12/99 Local Principal Investigator: A Randomized Double-Masked Controlled Trial of r-h CuZn Superoxide Dismutase for the Prevention of Bronchopulmonary Dysplasia.
Sponsored by Bio-Technology General Corp.
PI = Jonathan Davis, M.D., Winthrop University, New York.
Total support = \$3,750 per patient.
- 7/01/98 -7/17/02 Site Principal Investigator, Steering Committee Member
Early Non-Tidal vs Tidal Ventilation in Very Low Birth Weight Babies
Sponsor: Abbott Laboratories and SensorMedics Corp/Bird Products Corporation.
Support = \$1,200.00 per patient enrolled
- 3/30/01 – 9/16/04 Site Principal Investigator:
Synagis® Outcomes Registry
Sponsored by Medimmune, Inc.
Support: \$1700.00 Start Up cost + \$50.00 per child enrolled

11/21/05 – 2006 Principal Investigator
Sponsored by Inhibitex
A Phase I, Open Label, Multi-center Trial to Determine Antibody
Concentrations of Veronate in Premature Infants (birth wt. 500 –
1250 g). IgG-CL-008
Support: \$3000 per patient enrolled

MODERATOR:

1. 10/90 Co-Chairman, Neonatology Platform Session, Eastern Society for Pediatric Research, New York City, New York

BOOK CHAPTERS:

1. Hudak ML. Necrotizing Enterocolitis. In: Pediatrics (18th edition). Rudolph AM (ed). Appleton-Century-Crofts, New York, NY, 1987, pp 930-3.
- 2.. Hudak ML. Inborn Errors of Metabolism with Acute Neonatal Onset. In: Neonatology (1st edition). Gomella TL (ed). Appleton & Lange, Norwalk, CT, 1988, pp 240-7.
3. Hudak ML. Neural Tube Defects. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J. (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 516-22.
4. Hudak ML. Hydrocephalus. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 523-27.
5. Hudak ML. The Hypotonic Infant. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 536-40.
6. Hudak ML. Inborn Errors of Metabolism. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 432-38.
7. Hudak ML. Childhood Dysrhythmias. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 341-48.
8. Hudak ML. Endocarditis. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 349-54.
9. Hudak ML. Myopericardial Disease. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 355-62.
10. Hudak ML. Congestive Heart Failure. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 363-71.
11. Hudak ML. Respiratory Distress Syndrome. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 97-106.

12. Hudak ML. Chronic Lung Disease. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 107-14.
13. Hudak ML. Neonatal Jaundice. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 115-23.
14. Hudak ML. Necrotizing Enterocolitis. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 125-29.
15. Hudak ML. Surgical Emergencies of the Newborn. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 130-37.
16. Hudak ML. Neonatal Infection. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 138-47.
17. Hudak ML. Cyanosis. In: Pediatrics. Wood RA, Fosarelli P, Hudak ML, Lake A, Modlin J (eds). J.B. Lippincott Co., Philadelphia, PA, 1988, pp 148-57.
18. Hudak ML. Inborn Errors of Metabolism with Acute Neonatal Onset. In: Neonatology: Management, Procedures, On-call Problems, Diseases, Drugs (2nd edition). Gomella TL (ed). Appleton & Lange, Norwalk, CT, 1991, pp 316-326.
19. Hudak ML. Surfactant Therapy for Neonatal Respiratory Distress. In: Neonatology: Management, Procedures, On-Call Problems, Diseases, Drugs (2nd edition). Gomella TL (ed). Appleton, & Lange, Norwalk, CT, 1991, pp 114-121.
20. Jones MD Jr, Hudak ML. Regulation of the Fetal Cerebral Circulation. In: Fetal and Neonatal Physiology (1st edition). Polin R, Fox W (eds). W.B. Saunders Co., Philadelphia, PA, 1991, pp 682-690.
21. Hudak ML. Nutrition. In: Hospital Care of the Recovering NICU Patient. Jones MD Jr, Gleason CA, Lipstein S (eds). Williams and Wilkins, Baltimore, MD, 1991, pp 1-33.
22. Hudak ML. The Use of Antenatal Steroid Therapy for Anticipated Preterm Delivery. In: Prematurity: Antecedents, Treatment and Outcome (1st d). Witter F, Keith L (eds). Little Brown & Company, Boston, MA, 1993, pp 185-202.

PEER REVIEWED PUBLICATIONS:

1. Davidson RB, Hudak ML. The electronic structure of methylene radical anion and its dimer. J Am Chem Soc 1977;99:3918-3923.
2. Burdick JF, Helikson MA, Hudak ML, Williams GM. Revascularization for bilateral renal artery occlusion after umbilical artery catheterization. Surgery 1982;19:650-655.

3. Koehler RC, Traystman RJ, Rosenberg AA, Hudak ML, Jones MD Jr. Role of O₂-hemoglobin affinity in cerebrovascular response to carbon monoxide hypoxia. *Am J Physiol (Heart Circ Physiol 14)* 1983;245:H1019-H1023.
4. Hudak ML, Jones MD Jr, Brusilow SW. Differentiation of transient hyperammonemia of the newborn and urea cycle enzyme defects by clinical presentation. *Pediatr* 1985;107:712-719.
5. Hudak ML, Koehler RC, Rosenberg AA, Traystman RJ, Jones MD, Jr. The effect of hematocrit on cerebral blood flow. *Am J Physiol (Heart Circ Physiol 20)* 1986;251:H63-H70.
6. Rosenberg AA, Harris A, Koehler RC, Hudak ML, Jones MD, Jr. Role of O₂-hemoglobin affinity on regulation of cerebral blood flow in the fetal sheep. *Am J Physiol (Heart Circ Physiol 20)* 1986;251:H56-H62.
7. Massik J, Tang Y-L, Hudak ML, Koehler RC, Traystman RJ, Jones MD Jr. Effect of hematocrit on cerebral blood flow with induced polycythemia. *J Appl Physiol* 1987; 62:1090-1096.
8. Watson R, Kang JE, May M, Hudak M, Kickler T, Provost TT. Thrombocytopenia in the neonatal lupus syndrome. *Arch Dermatol* 1988;124:560-563.
9. Hudak ML, Tang Y-L, Massik J, Koehler RC, Traystman RJ, Jones, MD Jr. Baseline O₂ extraction influences cerebral blood flow response to hematocrit. *Am J Physiol (Heart Circ Physiol 23)* 1988;254:H156-H162.
10. Hudak ML, Jones MD Jr, Popel AS, Koehler RC, Traystman RJ, Zeger SC. Hemodilution causes size-dependent constriction of pial arterioles in the cat. *Am J Physiol (Heart Circ Physiol 26)* 1989;257:H912-H917.
11. Hudak BB, Allen MC, Hudak ML, Loughlin GM. Home oxygen therapy in infants less than 1000 grams. *Am J Dis Child* 1989;143:357-360.
12. Massik J, Jones MD Jr, Miyabe M, Tang Y-L, Hudak ML, Koehler RC, Traystman RJ. Hypercapnia and response of cerebral blood flow to hypoxia in newborn lambs. *J Appl Physiol* 1989;66:1065-1070.
13. Donohue PK, Hudak ML. Advances in surfactant replacement therapy for neonates. *J Am Acad Phys Assist* 1990;4:310-320.
14. Dohi S, Jones MD Jr, Hudak ML, Traystman RJ. Effects of cocaine on pial arterioles in cats. *Stroke* 1990;21:1710-1714.
15. Helou SM, Hudak ML, Jones MD, Jr. Cerebral blood flow response to hypercapnia in immature fetal sheep. *Am J Physiol (Heart Circ.Physiol 30)* 1991;261:H1366-H1370.

16. McKnight AA, Keyes WG, Hudak ML, Jones MD Jr. Oxygen free radicals and the cerebral arteriolar response to group B streptococci. *Pediatr Res* 1992;31:640-644.
17. Repka MX, Hudak ML, Parsa CF, Tielsch JM. Calf-lung surfactant extract prophylaxis and retinopathy of prematurity. *Ophthalmology* 1992;99:531-536.
18. Cummings JJ, Holm BA, Hudak ML, Hudak BB, Ferguson WH, Egan EA. A controlled comparison of four different surfactant preparations in surfactant-deficient preterm lambs. *Am Rev Respir Dis* 1992;145:999-1004.
19. Rogers BT, Msall ME, Owens T, Guernsey K, Brody A, Buck G, Hudak ML. Cystic periventricular leukomalacia and type of cerebral palsy in preterm infants. *J Pediatr* 1994;125(1):S1-8.
20. Taylor GA, Hudak ML. Color doppler ultrasound of changes in small vessel diameter and cerebral blood flow during acute anemia in the newborn lamb. *Invest Rad* 1994;9:188-194.
21. Hudak ML, Farrell EE, Rosenberg AA, Jung AL, Auten RL, Durand DJ, Horgan MJ, Buckwald S, Belcastro MR, Donohue PK, Carrion V, Maniscalco WW, Balsan MJ, Torres BA, Miller RR, Jansen RD, Graeber JE, Laskay KM, Matteson EJ, Egan EA, Brody AS, Martin DJ, Riddlesberger MM, Montgomery P. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. *J Pediatr* 1996;128:396-406.
22. Hudak ML, Martin DJ, Egan EA, Matteson EJ, Cummings J, Jung AL, Kimberlin LV, Auten RL, Rosenberg AA, Asselin JM, Belcastro MR, Donohue PK, Hamm CR, Jansen RD, Brody AS, Riddlesberger MM, Montgomery P. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. *Pediatrics* 1997;100:39-50.
23. Rogers B, Andrus J, Msall ME, Arvedson J, Sims J, Rossi T, Martin D, Hudak ML. Growth of preterm infants with cystic periventricular leukomalacia. *Dev Med and Child Neurol* 1998;40:580-586.
24. Hilfiker ML, Karamanoukian HL, Hudak M, Fisher J, Glick PL. Congenital diaphragmatic hernia and chromosomal abnormalities: report of a lethal association. *Pediatr Surg Int* 1998;13:550-552.
25. Sharan M, Popel AS, Hudak ML, Koehler RC, Traystman RJ, Jones MD. An analysis of hypoxia in sheep brain using a mathematical model. *Ann Biomed Eng* 1998;26:48-59.
26. Sharma R, Hudak ML, Perszyk AA, Premachandra BR, Li H, Monteiro C. Perinatal lethal form of Gaucher's Disease presenting with hemosiderosis. *Am J Perinatol* 2000;17:201-206.

27. Durand DJ, Asselin JM, Hudak ML, Aschner JL, McArtor RD, Cleary JP, VanMeurs KP, Stewart DL, Shoemaker CT, Wiswell TE, Courtney SE. Early high-frequency oscillatory ventilation versus synchronized intermittent mandatory ventilation in very low birth weight infants: a pilot study of two ventilation protocols. *J Perinatol* 2001;21:221-229.
28. Sullivan SE, Calhoun DA, Maheshwari A, Ashmeade TL, Auerback DA, Hudak ML, Beltz SE, Christensen RD on behalf of the Florida Collaborative Neonatology Clinical Trials Group. Tolerance of simulated amniotic fluid in premature neonates. *Pediatrics* 2002; 36:1518-1524.
29. Courtney SE, Durand DJ, Asselin JM, Hudak ML, Aschner JL, Shoemaker CT for the Neonatal Ventilation Study Group. High frequency oscillatory ventilation versus conventional mandatory ventilation for very-low-birth-weight infants. *N Engl J Med* 2002; 347:643-52.
30. Sharma R, Hudak ML, Premachandra BR, Stevens G, Monteiro CB, Bradshaw JA, Kaunitz AM, Hollister RA. Clinical manifestations of rotavirus infection in the neonatal intensive care unit. *Pediatr Infect Dis J* 2002; 21:1099-105.
31. Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T, Fishbein J, McRae P, Goessler M, Gatti A, Calcagno JA, Eki C, Harris KA, Joyave J, McFarland K, Protter P, Sullivan M, Stanford A, Lovett N, Ortiz M, Rojas S, Cyrus S, Cyrus J, Cohen S, Buchin D, Riordan L, Zuniga M, Shah R, Minard C, Quintin A, Douglas G, van Houten J, Freutner S, Chartrand S, Nowatzke P, Romero J, Rhodes T, Benoit M, Walter E, Walker L, DeBonnett L, Cross M, Free T, Martin S, Shank K, Guedes B, Atkinson LA, Halpin GJ, Rouse K, Hand I, Geiss D, Marshall JR, Burlison L, Boland J, Seybold K, Hunter V, Unfer S, Schmucker J, Gley M, Marcus M, Thompson P, Milla P, Young C, Zanni R, Zinno V, Fetter-Zarzeka A, Busey A, Sokunbi MA, Airington S, Richard N, Muraligopal V, Lewis S, Weber FT, Giordano BP, Linehan D, Roach J, Davis R, Rzepka AA, Booth T, Smeltzer D, Walsh J, Arispe E, Rowley R, Bolling C, Botts T, Haskett K, Raby D, Batiz E, Gelfand A, Farrell L, Butler S, Colby L, Schochet P, Bentler J, Hirsch D, Wilkinson L, Aaronson A, Bennett E, Wingate J, Quinn D, Komendowski K, Deckard M, Frogel M, Nerwen C, Copenhagen S, Prater M, Wolsztein J, Mackey K, Benbow M, Naranjo M, Hensley S, Hayes C, Sadeghi H, Lawson SM, McCall M, Combs K, Ledbetter J, Sarnosky K, Swafford C, Speer M, Barton WJ, Mink JW, Lemm D, Hudak M, Case E, Rowen J, Fuentes S, Pane C, Richardson L, Chavarria C, Cassino D, Ghaffari K, Carroll C, Lee H, Guclu L, Johnson C, Blum V, Boron ML, Sorrentino M, Hirsch RL, Van Veldhuisen PC, Smith C. Palivizumab Outcomes Registry Study Group. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from the Palivizumab outcome registry. *Pediatr Pulmonol* 2003; 35:484-489.
32. Sharma R, Garrison RD, Tepas JJ, Mollitt DL, Piepe P, Hudak ML, Bradshaw JA, Stevens G, Premachandra BR. Rotavirus-associated necrotizing enterocolitis: an insight into a potentially preventable disease? *J Pediatr Surg* 2004; 39:453-457.

33. Sharma R, Tepas JJ III, Mollitt DL, Hudak ML, Garrison RD, Sharma M, Wludyka PS. Portal venous gas and surgical outcome of neonatal necrotizing enterocolitis. *J Pediatr Surg* 2005; 40: 371-376.
34. Sharma R, Tepas JJ III, Hudak ML, Pieper P, Teng RJ, Raja S, Sharma M. Neonatal gut injury and infection rate: impact of surgical debridement on outcome. *Pediatr Surg Int* 2005; 21 (12):977-82.
35. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, Perritt R, Higgins RD, Oh W, Hudak ML, Laptook R, Shankaran S, Finer NN, Carlo WA, Kennedy KA, Fridriksson JH, Steinhorn RH, Sokol GM, Konduri GG, Aschner JL, Stoll BJ, D'Angio CT, Stevenson DK. Inhaled nitric oxide for premature infants with severe respiratory failure. *N Engl J Med* 2005; 353:13-22.
36. Tepas JJ III, Sharma R, Hudak ML, Garrison RD, Pieper P. Coming full circle: an evidence based definition of the timing and type of surgical management of very low-birth-weight (<1000 g) infants with signs of acute intestinal perforation. *J Pediatr Surg* 2006; 41:418-422.
37. Teng RJ, Wu TJ, Sharma R, Garrison R, Hudak ML. Early neonatal hypotension in premature infants born to pre-eclamptic mothers. *J Perinatol* 2006; 26:471-5.
38. Sharma R, Hudak ML, Tepas JJ III, Wludyka P, Bradshaw JA, Marvin WJ, Pieper P. Impact of gestational age on the clinical presentation and surgical outcome of necrotizing enterocolitis. *J Perinatol* 2006; 26:342-7.
39. Ballard RA, Troug WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, Walsh MC, Durand DJ, Mayock DE, Eichenwald EC, Null DR, Hudak ML, Puri AR, Golombek SG, Courtney SE, Stewart DL, Welty SE, Phibbs RH, Hibbs AM, Luan X, Wadlinger SR, Asselin JM, Coburn CE for the NO/CLD Study Group. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. *N Engl J Med* 2006; 355:343-53.
40. Ward RM, Benitz WE, Benjamin DK Jr., Blackmon L, Giacoia GP, Hudak M, Lasky T, Rodriguez W, Selen A. Criteria supporting the study of drugs in the newborn. *Clin Ther* 2006;28:1385-98.
41. Sharma R, Tepas JJ III, Hudak ML, Mollitt DL, Wludyka PS, Teng RJ, Bangalore PR. Neonatal gut barrier and multiple organ failure: role of endotoxin and proinflammatory cytokines in sepsis and necrotizing enterocolitis. *J Pediatr Surg* 2007;42:454-61.

MANUSCRIPTS IN PREPARATION:

1. Sharma R, Hudak ML, Wludyka W, Teng RJ, Tepas JJ III, Haycook L. Early postnatal maternal milk feedings reduce risk for late onset blood stream infections in very low birth weight infants.

2. Sharma R, Hudak ML, Marvin W, Tepas JJ, Garrison RD, Renfro WH, Hastings LK and Peter Wludyka. Bowel perforation and necrotizing enterocolitis (NEC): Role of indomethacin in very low birth weight infants.

PUBLICATIONS / NON-REFEREED JOURNALS / GUEST EDITOR:

1. Hudak ML. Commentary in: The Year Book of Pediatrics 1991, Oski FA (ed). Mosby-Year Book Inc., St. Louis, MO. 1991;31-32.
2. Joy S, Hudak ML. Infant mortality trends in Duval County, Florida. In press, Jacksonville Medical Journal, Sep. 2001.
3. Hudak ML. Thoughts about neonatal and infant mortality trends. Onyx Magazine. Sep.2001; 20-21.
4. Hudak ML, Guest Editor, The Florida Society of Neonatologists NeoNotes, A Journal Club for Neonatologists. 1) Hypotensive Extremely LBW Infants Have Reduced Cerebral Blood Flow. 2) Randomized Controlled Trial of Slow vs Rapid Feeding Volume Advancement in Preterm Infants. 3) Prophylaxis of Early Adrenal Insufficiency to Prevent Bronchopulmonary Dysplasia: A Multicenter Trial. December 2004; V12:112.
5. Hudak ML, Guest Editor, The Florida Society of Neonatologists NeoNotes, A Journal Club for Neonatologists 1) Is Surfactant Therapy Beneficial in the Treatment of the Term Newborn Infant with Congenital Diaphragmatic Hernia? 2) Survey of Vitamin A Supplementation for Extremely LBW Infants: is clinical practice consistent with the evidence? 3) Neonatal Brain MRI Before Discharge is Better Than Serial Cranial Ultrasound in Predicting Cerebral Palsy in VLBW preterm Infants. 4) Initial Hypoglycemia and Neonatal Brain Injury in Term Infants with Severe Fetal Acidemia. October 2004; V10:110.
6. Hudak ML, Guest Editor, Florida Society of Neonatologists NeoNotes. 1) CPAP in Extremely LBW Infants; 2) A Feasibility Trial, Paradoxical Impact of body Positioning on Gastroesophageal Reflux and Gastric Emptying in the Premature Neonate, 3) Initial Hypoglycemia and Neonatal Brain Injury in Term Infants with Severe Fetal Acidemia. September 2004, V9:19.
7. Hudak ML, Guest Editor, Florida Society of Neonatologists NeoNotes. 1) New Hyperbilirubinemia Guidelines, 2) Jaundice and kernicterus, 3) Meconium Ileus in Preterm Infants, July 2004, V7:17.
8. Hudak ML, Review & Commentary, "Prophylaxis vs Rescue Surfactant Treatment For Very Premature Infants", Johns Hopkins eNeonatal Review, March 15, 2004; V 1:7.
9. Hudak ML, Guest Editor, The Florida Society of Neonatologists NeoNotes, A Journal Club For Neonatologists. 1) Combination of Early Perinatal Factors to Identify Near-Term and Term Neonates for Neuroprotection. 2) The Epidemiology of Respiratory Failure in

Neonates Born at an Estimated Gestational Age of 34 Weeks or More. 3) Practice Variation in Suspected Neonatal Sepsis: A Costly Problem in Neonatal Intensive Care. 4) Improved Outcome of Extremely LBW Infants with Tegaderm Application to Skin. April 2005; V6:14.

PUBLICATIONS / ABSTRACTS:

1. Hudak ML, Jones MD Jr, Brusilow S. Transient hyperammonemia of the newborn (THAN) and urea cycle enzyme defects (UCED) differentiated by clinical presentation. *Pediatr Res* 1984;18:328A. (**Poster presentation**, Society of Pediatric Research Annual Meeting, 5/84)
2. Hudak ML, Koehler RC, Rosenberg AA, Traystman RJ, Jones MD Jr. The effect of hematocrit on cerebral blood flow: differentiation of viscosity and oxygen content effects. (**Poster presentation**, Microcirculatory Society Annual Meeting, 1985)
3. Hudak ML, Koehler RC, Rosenberg AA, Traystman RJ, Jones MD Jr. The effect of hematocrit on cerebral blood flow (CBF): differentiation of viscosity and oxygen content effects. *Fed Proc* 1985;44:1587. (**Poster presentation**, Federation of American Society of Experimental Biology Annual Meeting, 4/85, Anaheim, CA)
4. Massik J, Hudak ML, Koehler RC, Traystman RJ, Jones MD Jr. Combined effect on hypoxic hypoxia (HH) and hypercapnia on cerebral blood flow (CBF) in lambs. (**Poster presentation**, Microcirculatory Society Annual Meeting, 4/85)
5. Massik J, Hudak ML, Koehler RC, Traystman RJ, Jones MD Jr. Combined effect on hypoxic hypoxia (HH) and hypercapnia on cerebral blood flow (CBF) in lambs. *Fed Proc* 1985;44:3498. (**Poster presentation**, Federation of American Society of Experimental Biology, 4/85)
6. Massik J, Hudak ML, Koehler RC, Traystman RJ, Jones MD Jr. Combined effect on hypoxic hypoxia (HH) and hypercapnia on cerebral blood flow (CBF) in lambs. *Pediatr Res* 1985;19:352A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/85)
7. Hudak ML, Koehler RC, Rosenberg AA, Traystman RJ, Jones MD Jr. Viscosity regulates cerebral blood flow independently of arterial oxygen content. *Pediatr Res* 1985;19:346A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/85)
8. Hudak ML, Traystman RJ, Jones MD Jr. Baseline cerebral blood flow regulates response to an independent increase in red blood cell concentration. *Pediatr Res* 1986;20:350A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/86)
9. Massik J Tang Y-L, Hudak ML, Koehler RC, Traystman RJ, Jones MD Jr. Effect of hematocrit (Hct) on cerebral blood flow (CBF) during induced polycythemia in lambs. *Pediatr Res* 1986;20:354A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/86)

10. Massik J, Tang Y-L, Hudak ML, Koehler RC, Traystman RJ, Jones MD Jr. Effect of hematocrit on cerebral blood flow in lambs. *Fed Proc* 1986;45:760. (**Poster presentation**, Federation of American Society of Experimental Biology, 4/86)
11. Hudak ML, Koehler RC, Rosenberg AA, Traystman RJ, Jones MD Jr. Effect of hematocrit on cerebral blood flow (CBF) in lambs. *Fed Am Soc Exp Biol* 1987;43:897. (**Platform presentation**, Federation of American Society of Experimental Biology, 4/84, St. Louis, MO)
12. Hudak ML, Jones MD Jr, Traystman RJ, Popel AS. The effect of hemodilution on pial artery diameter in the cat. *FASEB J* 1988;2:A1868. (**Poster presentation**, Microcirculatory Society, 1988)
13. Hudak ML, Jones MD Jr, Traystman RJ, Popel A. Hemodilution causes size-dependent constriction of meningeal arteries in the cat. *Pediatr Res* 1988;23:410A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/88)
14. Keyes WG[#], Hudak ML, Jones MD Jr. Effect of Group B streptococci (GBS) on meningeal vessels. *Pediatr Res* 1988;23:474A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/88)
15. Jones MD Jr, Hudak ML, Koehler RC, Traystman RJ, Popel AS. Hemodilution constricts pial arterioles in the cat. *J Cereb Blood Flow Metab* 1989;9(supp.1): S392. (**Poster presentation**, XIV International Symposium on Cerebral Blood Flow and Metabolism – Brain '89, Bologna, Italy)
16. Keyes WG[#], Jones MD Jr, Hudak ML. Group B streptococci cause vasodilation and loss of CO₂ responsiveness in rat pial arterioles. *FASEB J* 1989;3:A1390. (**Poster presentation**, Federation of American Society of Experimental Biology Annual Meeting, 4/89).
17. Hudak BB, Allen MC, Loughlin GM, Hudak ML. Prophylactic surfactant decreases chronic lung disease in <1000 gram infants. *Pediatr Res* 1990;27:307A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/90)
18. Hudak ML, Taylor G, Jones MD Jr. Hemodilution causes dilation of cerebral arteries as assessed by color doppler imaging. *Pediatr Res* 1990;27:209A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/90)
19. Hoon A, Taylor GA, Allen MC, Hudak ML, Gittelsohn A. Prophylactic surfactant, survival, and IVH in infants < 1000 grams. *Pediatr Res* 1990;27:309A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/90)
20. Dohi S, Jones MD Jr, Hudak ML, Traystman RJ. Topical cocaine dilates pial arterioles. *FASEB J*. 1990;4:A1096. (**Poster presentation**, Federation of American Society for Experimental Biology, 4/90)

21. Repka MX, Parsa CF, Hudak ML. Surfactant prophylaxis and retinopathy of prematurity. (**Poster presentation**, ARVO, 1991)
22. Cummings J, Holm B, Hudak M, Hudak B, Ferguson W, Egan E. Effects of three surfactants on gas exchange and pulmonary mechanics in premature lambs. Am Rev Resp Dis 1991;143:A128. (**Poster presentation**, American Thoracic Society Annual Meeting, 4/91)
23. Glick PL, Holm BA, Allen JE, Bruce J, Hudak ML. Exogenous surfactant therapy (EST) for infants with CDH: a double-masked randomized multicenter controlled trial. (**Platform presentation**, Children's National Medical Center Annual ECMO Symposium, 2/92, Vail, CO)
24. Hudak ML, Matteson EJ, Baus JA, et al. Infasurf vs. Exosurf for the prophylaxis of RDS: a ten center randomized double-masked comparison trial. Pediatr Res 1994;35:231A. (**Platform presentation**, Society for Pediatric Research Annual Meeting, 5/94, San Diego, CA)
25. Hudak ML, Matteson EJ, Baus JA, et al. Infasurf vs. Exosurf for the treatment of RDS: a 21 center randomized double-masked comparison trial. Pediatr Res 1994;35:231A. (**Platform presentation**, Society for Pediatric Research Annual Meeting, 5/94, San Diego, CA)
26. Rogers BT, Zorn WA, Bregman J, Allen MC, Goldstein RF, Buckwald S, Msall ME, Hudak ML. Correlation of neonatal neurosonographic outcomes and growth at one year in premature infants. (**Poster presentation**, American Academy of Cerebral Palsy and Developmental Medicine Annual Meeting, 10/95)
27. Rogers BT, Hassan MB, Msall ME, Yu S, Arvedson J, Buck G, Dua R, Hudak ML. Oral feeding efficiency of preterm infants at 35 weeks (wks) postmenstrual age (PMA). (**Platform presentation**, American Academy of Cerebral Palsy and Developmental Medicine Annual Meeting, 10/95)
28. Hudak ML, Buck G, Martin D, et al. Cystic periventricular leukomalacia (CPVL) is a more important predictor of neurodevelopmental disability than grade 3-4 IVH (IVH3/4). Pediatr Res 1995;37:101A. (Poster presentation, Society of Pediatric Research Annual Meeting, 5/95, San Francisco, CA)
29. Sukumar M, Martin DJ, Rogers BT, Hudak ML. Evidence for prenatal, perinatal and postnatal antecedents of cystic periventricular leukomalacia (CPVL). Pediatr Res 1995;37:102A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/95, San Francisco, CA)
30. Rogers B, Zorn W, Martin D, Sukumar M#, Msall M, Hudak M. Cystic periventricular leukomalacia (CPVL) predicts significantly worse neurodevelopmental (ND) outcome than grade 4 intraventricular hemorrhage (IHV4). Pediatr Res 1995;37:103A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/95, San Francisco, CA)

31. Rogers B, Zorn W, Lynch L, Bregman J, Allen M, Goldstein R, Msall M, Hudak ML. One year neurodevelopmental (ND) outcome of infants < 29 wk enrolled in a multicenter comparison trial of Exosurf (EXO) and Infasurf (INFA) prophylaxis of RDS. *Pediatr Res* 1995;37:104A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/95, San Francisco, CA)
32. Zorn W, Rogers B, Lynch L, Buckwald S, Shah P, Bregman J, Allen M, Goldstein R, Msall M, Hudak ML. One year neurodevelopmental (ND) outcome of infants < 1350 G enrolled in a multicenter comparison trial of Exosurf (EXO) and Infasurf (INFA) for the treatment of RDS. *Pediatr Res* 1995;37:105A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/95, San Francisco, CA)
33. Rogers B, Zorn W, Martin D, Sukumar M, Msall M, Hudak ML. Cystic periventricular leukomalacia (CPVL) predicts significantly worse neurodevelopmental (ND) outcome than grade 4 intraventricular hemorrhage (IHV4). (**Poster presentation**, Society for developmental Pediatrics Annual Meeting, Scientific Session, 5/95)
34. Rogers BT, Hassan MB, Msall ME, Arvedson J, Buck G, Dua R, Yu S, Hudak ML. Oral feeding efficiency and neurodevelopmental status of preterm infants at 35 weeks (wks) postmenstrual age (PMA). (Poster presentation, Society for Developmental Pediatrics Annual Meeting, Scientific Session, 5/95)
35. Martin DJ, Rogers BT, Msall ME, Hudak ML, Zorn W, Sukumar M#. Comparison of the parenchymal lesions in grade IV intraventricular hemorrhage (IVH4) and cystic eriventricular leukomalacia (CPVL) and their neurodevelopmental sequelae. (**Platform presentation**, European Society of Pediatric Radiology Annual Meeting, 5/95)
36. Martin DJ, Sukumar M#, Rogers BT, Hudak ML. Evidence of prenatal, perinatal, and postnatal antecedents of periventricular leukomalacia. (**Platform presentation**, Society for Pediatric Radiology Annual Meeting, 4/95, Washington, DC)
37. Martin D, Hudak ML, Rogers B, Sukumar M#. Cystic periventricular leukomalacia -pre-, peri-, and postnatal origins. (**Poster presentation**, XVth European Congress of Perinatal Medicine, September 11, 1996)
38. Rogers BT, Zorn WA, Msall ME, Lynch L, Bregman J, Buckwald S, Shah P, Goldstein RF, Allen MC, Hudak ML. Two year neurodevelopmental outcome of infants < 1350G enrolled in a multicenter comparison trial of Exosurf (EXO) and Infasurf (INFA) for the treatment of RDS. *Pediatr Res* 1996;39:277A).
39. Rogers BT, Andrus J, Msall ME, Arvedson J, Sims J, Rossi T, Martin D, Hudak M. Dysphagia and growth failure in preterm infants with cystic periventricular leukomalacia. *Pediatr Res* 1996;39:277A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/96, Washington, DC)

40. Rogers BT, Hassan MG, Msall ME, London PV, Reynolds JD, Dua R, Hudak M. Visual attention of preterm (PT) infants at 35 weeks (WKS) post menstrual age (PMA) and neurodevelopmental (ND) outcome. *Pediatr Res* 1996;39:277A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/96, Washington, DC)
41. Zorn WA, Msall ME, Rogers BT, Lynch L, Bregman J, Goldstein RF, Allen MC, Hudak ML. Two year neurodevelopmental outcome of infants < 29 Weeks enrolled in a multicenter comparison trial of Exosurf (EXO) and Infasurf (INFA) prophylaxis for RDS. *Pediatr Res* 1996;39:285A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/96, Washington, DC)
42. Msall ME, Zorn WA, Rogers BT, Lynch L, Buckwald S, Shah P, Bregman J, Goldstein R, Allen M, Sim J, Hudak ML. Prediction of developmental outcome at two years in very low birth weight (VLBW) infants after surfactant. *Pediatr Res* 1996;39:273A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/96, Washington, DC)
43. Reese M, Rogers B, Martin D, Andrus J, Msall M, Hudak M. Health impairments in preterm infants with cystic periventricular leukomalacia (CPVL). *Pediatr Res* 1997;41:209A. (**Poster presentation**, Society for Pediatric Research Annual Meeting, 5/97, Washington, DC)
44. Sharma R, Premachandra BR, Renfro W, Hudak ML. Effect of corticosteroid (CS) administration on the incidence of neonatal necrotizing enterocolitis (NEC) in low birth weight (LBW) infants. *Pediatr Res* 1997;41:226A. (**Poster symposium presentation**, Society for Pediatric Research Annual Meeting, 5/97, Washington, DC)
45. Courtney SE, Durand DJ, Asselin JM, Wiswell TE, Hudak ML, Aschner J, McArtor R, Cleary J, Van Meurs KP, Stewart DL, Shoemaker CT. A pilot study of early non-tidal vs. tidal ventilation in premature infants. *Pediatr Res* 1998;43:171A. (**Poster presentation**, Pediatric Academic Societies Annual Meeting, 5/98, New Orleans, LA)
46. Davis JM, Rosenfeld WN, Richter SE, Parad R, Gewolb IH, Couser R, Price A, Kinsella JP, Donn SM, Gerstsmann G, Ramanathan R, Raju T, Hudak M, Baumgart S, Carlo W, Davidson D, Mammel MC, Parton L, Saleno L, Huang W, Barton N. The effects of multiple doses of recombinant human CuZn superoxide dismutase (rhSOD) in premature infants with respiratory distress syndrome (RDS). *Pediatr Res* 1999;45:193A. (**Poster presentation**, Pediatric Academic Societies Annual Meeting, 5/99, San Francisco, CA)
47. Msall ME, Rogers B T, Allen M, Bregman J, Zorn W, Tremont M R, Hudak ML. Neurodevelopmental impairments and functional status in preschool children of very low birth weight status enrolled in surfactant clinical trials. (**Platform presentation**, American Academy of Cerebral Palsy and Developmental Medicine Annual Meeting, 9/00)
48. Hudak ML, Chartrand SA, and the Synagis® Outcomes Registry: Synagis® (Palivizumab) Prophylaxis of Respiratory Syncytial Virus (RSV) Infection – Patient Demographics and Preliminary Results from the 2000-2001 Synagis® Outcomes Registry. (**Poster**

presentation, to be presented at the American Pediatric Societies Meeting, Oct, 2001 San Francisco, CA)

49. Courtney SE, Durand DJ, Asselin JM, RRT, MS, Hudak, ML, MD, Aschner, JL MD and Shoemaker, CT,MD. The Neonatal Ventilation Study Group. Early high frequency oscillatory ventilation (HFOV) vs synchronized intermittent mandatory ventilation (SIMV) in very low birth weight (VLBW) infants. *Pediatr Res* 2001;49:101A. (**Platform presentation**, Pediatric Academic Societies Annual Meeting, May, 2001, Baltimore, MD)
50. Sullivan SE, Calhoun DA, Ashmeade TL, Auerbach DA, Hudak ML, Beltz SE, Hutson A, Christensen RD. Simulated amniotic fluid for enteral administration to premature neonates who are otherwise "NPO": a multicentered, phase I, dose-escalation trial. *Pediatr Res* 2001;49:150A. (**Poster presentation**, Pediatric Academic Societies Annual Meeting, May,2001, Baltimore, MD)
51. Michele TM, Couser R, Parad R, Gewolb JH, Huang W, Davis JM for the r-hCuZnSOD Neonatal Study Group. Recombinant human CU/ZN superoxide dismutase decreases asthma medication use at one year follow-up in premature infants with respiratory distress syndrome. (**Poster presentation**, American Academy of Asthma, Allergy and Clinical Immunology Annual Meeting, 2001)
52. Courtney SE, Durand DJ, Asselin JM, Hudak ML and the Neonatal Ventilation Study Group. Early high frequency oscillatory ventilation (HFOV) vs synchronized intermittent mandatory ventilation (SIMV) in very low birth weight (VLBW) infants. (**Poster presentation**, Pediatric Academic Societies Annual Meeting, 3/01, Scottsdale, AZ)
53. Hudak ML, Chartrand SA, and the Synagis® Outcomes Registry: Synagis® (Palivizumab) Prophylaxis of Respiratory Syncytial Virus (RSV) Infection – Consistently Low RSV Hospitalization Rates Reported for Children Receiving Synagis® Nationwide. (**Poster presentation**), presented at the American Academy Of Pediatrics Meeting, 10/02, Boston, MA)
54. Mark Hudak, MD and the Palivizumab Outcomes Registry, University of Florida Jacksonville, Jacksonville, Florida. Palvizumab Prophylaxis of RSV Disease – Results of 5,097 Children from the 2001-2002 Registry (**Poster presentation**). Presented at the AAP 2002 National Conference and Exhibition October 19 – 23, 2002.
55. Sharma R, Hudak ML, Garrison RD, Marvin W, Gordon V, Raja S. Characteristics of necrotizing enterocolitis in extremely Low Birth Weight (ELBW) and Very Low Birth Weight Infants (VLBW). *Pediatr Res* 46 (4): Abstract#2856, 2003.
56. Sharma R, Garrison RD, Tepas JJ, Mollitt DL, Pieper P, Hudak ML, Bradshaw JA, Stevens G, Premachandra BR. Rotavirus associated necrotizing enterocolitis: An insight into a potentially preventable disease? Presented at The 34th Annual Meeting of the American Pediatric Surgical Association at Fort Lauderdale, FL, USA, May 25-28, 2003.

57. Sharma R, Hudak ML, Garrison RD, Marvin W, Tepas JJ, Renfro WH, Hastings LK and Peter Wludyka. Bowel perforation and necrotizing enterocolitis (NEC): Role of Indomethacin in very low birth weight infants. Presented, May 3, at the Annual meeting of the American Society of Pediatric Research, 2004, May 1-4, at Moscone West Convention Center, San Francisco, USA, 2004.
58. Sharma, R, Tepas III JJ, Hudak ML., Wludyka PS, Mollitt D L., Garrison RD, Bradshaw JA, Sharma M. Portal venous gas and surgical outcome of neonatal necrotizing enterocolitis. Presented, 28th July, 2004 at the 51st Annual International Congress of Paediatric Surgeons under the auspices of the British Associations of Paediatric Surgeons, 27th-30th July, at Examination Hall, Oxford University, Oxford, UK, 2004.
59. Sharma R, Tepas JJ III, Hudak ML, Pieper P, Teng RJ, Raja S, Sharma M. Neonatal gut-injury and infection rate: Impact of surgical debridement. Presented at the 8th Southeast European Symposium of Paediatric Surgery on "Infectious Problems in Paediatric Surgery" on September 25th, 2004 at auditorium of institute of Pathology, University Hospital of Graz under the auspices of European Pediatric Surgical Association, Graz, Austria, 2004.
60. Teng RJ, Wu TJ, Sharma R, Garrison RD, Hudak ML. Early neonatal hypotension is associated with severe intraventricular hemorrhage in premature (<30 wk) infants. *Pediatr Res* 46 (4): Abstract# xxxx, 2005.
61. Belsare D, Teng RJ, Sharma R, Wu TJ, Garrison RD, Hudak ML. Recombinant human colony stimulating factor does not prevent nosocomial infection in very low birth weight infants with early neutropenia. Presented at the Annual Pediatric Societies' Meeting, May 14-17, 2005, Washington DC. USA 2005.
62. Tepas JJ III, Sharma R, Hudak ML, Garrison RD, Pieper P. Coming Full Circle: An Evidence Based Definition Of The Timing And Type Of Surgical Management Of Very Low Birth Weight (VLBW: <1000 gm.) Infants With Signs Of Acute Intestinal Perforation. To be presented on 15th July, 2005 at the 52nd Annual International Congress of Paediatric Surgeons under the auspices of the British Associations of Paediatric Surgeons, 12th-15th July, 2005, Dublin, Ireland, 2005.
63. Sharma R, JJ Tepas III, Mollitt DL, Teng RJ, Hudak ML, and Wludyka P. The Gut is the promoter of multiple organ failure (MOF) and mortality in the premature infant. To be presented on 15th July, 2005 at the 52nd Annual International Congress of Paediatric Surgeons under the auspices of the British Associations of Paediatric Surgeons, 12th-15th July, 2005, Dublin, Ireland, 2005.
64. Sharma R, , Hudak ML, JJ Tepas III, Wludyka P, Marvin WJ, Bradshaw JA, Pieper P. Impact of Gestational Age on the Clinical Presentation and Surgical Outcome of Necrotizing Enterocolitis. Presented at the 37th Annual Meeting of the Canadian Association of Paediatric Surgeons, Québec City, Québec, Canada, September 22nd - 25th, 2005.
65. Sharma R, , Hudak ML, Wludyka W, Teng RJ, Tepas JJ III, Haycook L. Early Postnatal Maternal Milk Feedings Reduce Risk for Late Onset Blood Stream Infections in Very Low Birth Weight Infants. Presented, April 29th, at the Annual meeting of the American Society for Pediatric

Research, 2006, April 29-May 3, 1-4, at Moscone West Convention Center, San Francisco, USA, 2006.

66. Teng RJ, Williams P, Sharma R, Garrison RD, Hudak M. Evaluation of a Transcutaneous Bilirubinometer (Bilichek) as an Outpatient Screening Tool for Neonatal Hyperbilirubinemia (NH). Presented, May 2, at the Annual meeting of the American Society for Pediatric Research, 2006, April 29-May 3, 1-4, at Moscone West Convention Center, San Francisco, USA, 2006.
67. Sharma R, Hudak ML, Tepas JJ III, Wludyka PS, Marvin WJ, Bradshaw JA, Pieper P. Impact of Gestational Age on the Clinical Presentation and Surgical Outcome of Necrotizing Enterocolitis. Annual Faculty Research day at Gainesville on April 10th, 2006.

LECTURES / INVITED / INTERNATIONAL:

1. "Update on Neonatal Cardiopulmonary Therapies"; The Hong Kong Society of Neonatal Medicine, Hong Kong, China on October 17, 2001.
2. "Comparison of Short and Long-Term Pulmonary Outcomes in Infants Treated with Synthetic vs. Natural Surfactant" given at the UK Medical Research Council, 3/01, London, England
3. "Update on Nitric Oxide Therapy in Term and Preterm Infants". The Hong Kong Society of Neonatal Medicine, Hong Kong, China on June 3, 2005.
4. "What Do We Do with Nitric Oxide in Preterm Infants?" Presented at the First Neonatal Symposium, Beijing Children's Hospital, Beijing, China, June 2005.
5. "Hypothermia as a Treatment for Neonatal Asphyxia: State of the Evidence." Presented at the Neonatal Symposium, Beijing Children's Hospital, Beijing, China, November 2007.
6. "Inhaled NO in Premature Infants: The Data Are In, Now What to do?" Presented at the Neonatal Symposium, Beijing Children's Hospital, Beijing, China, November 2007.
7. "Rationale and Evidence for Hypothermia in the Treatment of Neonatal Asphyxia". Presented at The Hong Kong Society of Neonatal Medicine, Kowloon Shrgri-La, Kowloon, Hong Kong, November 2007.

LECTURES / INVITED / NATIONAL (Selected List):

1. Invited Speaker – "Managing Post Delivery Respiratory Distress" presented at the 13th Annual National Conference on Pediatric Lung and Allergic Diseases; Ponte Vedra Beach, Florida, May 1, 1993.

2. Invited Speaker – “Evolving Trends in Surfactant Therapy for the 1990's" presented at the 13th Annual National Conference on Pediatric Lung and Allergic Diseases; Ponte Vedra Beach, Florida, April 30, 1993.
3. Invited Speaker – “Neonatal Resuscitation” presented at the 13th Annual National Conference on Pediatric Lung and Allergic Diseases; Ponte Vedra Beach, Florida, April 30, 1993.
4. Invited Speaker - "Considerations in Designing Surfactant Comparison Trials" presented at Newborn Medicine Update 1993; Marina del Rey, California, October 15, 1993.
5. Invited Speaker - "Efficacy and Clinical Indications for Surfactant Therapy", Critical Care Grand Rounds, The Buffalo General Hospital, Buffalo, New York, December 21, 1994.
6. Invited Speaker - “Regulatory Considerations in Monitoring Multicenter Clinical Trials” presented at Protection of Human Subjects in Research; Hyatt Regency, Buffalo, New York, September 23, 1994.
7. Invited Speaker – “Potential Synergy between Inhaled Nitric Oxide and Surfactant for Treatment of Term Infants with Parenchymal Lung Disease, Pulmonary Hypertension, and Respiratory Failure: A Pilot Study” presented at Hot Topics in Neonatology, Washington D.C., December 1995.
8. Invited Speaker - "Liquid Ventilation" presented at Controversies in Obstetrics and Gynecology and all that Jazz conference at Baptist Medical Center, Jacksonville, Florida, October 11, 1996.
9. Invited Speaker - "Nitric Oxide Therapy" presented at American Lung Association River City Symposium, Amelia Island, Florida, August 15, 1996.
10. Invited Speaker - "Issues and Clinical Trials in Novel Therapies in Term Babies with Pulmonary Hypertension" presented at The 12th Annual CNMC Symposium of ECMO and Advanced Therapies for Respiratory Failure, Keystone, Colorado, February 27, 1996.
11. Invited Speaker - "Nitric Oxide and Surfactant Interactions in Infants with Parenchymal Lung Disease and Pulmonary Hypertension" presented at Hot Topics '95' in Neonatology, Washington, DC, December 3, 1996.
12. Invited Speaker - "Clinical Trials in Neonatology: History and Design Considerations" presented at Management of the Tiny Baby Conference, Orlando, Florida, February 15, 1997.
13. Visiting Professor – “Controversial Issues in Clinical Research” presented at Citywide Neonatology Conference at Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland, September 5, 2001.

14. Visiting Professor - "Perils and Pitfalls of Clinical Trials in Neonatology" presented at Grand Rounds at Kapiolani Medical Center, University of Hawaii, John A. Burns School of Medicine, Honolulu, Hawaii, August 23, 2001.
15. Visiting Professor - "Perils and Pitfalls of Clinical Trials in Neonatology" presented at Grand Rounds at Jackson Medical Center, University of Miami, Miami, Florida, August 7, 2001.
16. Invited Speaker – "A Potpourri of Advances in the Treatment of Neonatal Lung Disease", American Lung Association's Fourteenth Annual Pulmonary Critical Care Symposium, Jacksonville Marriott Hotel, Jacksonville, Florida, March 29, 2001.
17. Invited Speaker – "Clinical Trial Design Issues for Studies of Proton Pump Inhibitors in Neonates" presented at the FDA Pediatric Sub-Committee Meeting in Washington, DC, June 11, 2003.
18. Invited Speaker – "A Few Clinical Observations on Outcomes Research" presented during the University of Florida Research Day Celebration in the Learning Resource Center in Jacksonville, FL, April 9, 2003.
19. Invited Speaker -- "Prevention of Kernicterus; New Guidelines for Management of Hyperbillirubinemia". Presented at the Fourth Annual Pediatric Symposium sponsored by Baptist Children's Hospital in Miami, Florida, March 12, 2005.

LECTURES / INVITED / LOCAL & REGIONAL:

1. Invited Speaker - "Surfactants for Prevention and Treatment of Respiratory Distress Syndrome", State University of New York at Buffalo, Department of Pediatrics Faculty Research Conference, November 9, 1994
2. Invited Speaker – "Prenatal Group B Streptococcal Prophylaxis" presented at Baptist/St. Vincent's OB/GYN quarterly meeting, Baptist Medical Center, Jacksonville, Florida, October 24, 1996.
3. Invited Speaker - "Seminar on Prenatal Risk Factors for Abnormal Neurodevelopmental Outcomes" presented to Developmental Variations Class at University of North Florida, Jacksonville, Florida, September 9, 1996.
4. Invited Speaker - "Nitric Oxide Therapy" presented to neonatal nurse practitioners and physician assistants, Wolfson Children's Hospital, Jacksonville, Florida, September 3 and 6, 1996
5. Invited Speaker - "Observations from Clinical Trials of Surfactant Therapy" presented at Grand Rounds at Wolfson Children's Hospital, Jacksonville, Florida, July 10, 1996
6. Invited Speaker – "RSV Diseases in Pediatric Patients", Grand Rounds at Wolfson Children's Hospital, Jacksonville, Florida, March 26, 1997

7. Invited Speaker – “Biochemical, Biophysical and Clinical Differences Among faculty and fellows, Shands Jacksonville (formerly University Medical Center), Jacksonville, Florida, February 25, 1997.
8. Invited Speaker – “Pre-clinical and Clinical Comparisons of Surfactant Therapies for Respiratory Distress Syndrome (RDS)”. Grand Rounds at Shands Jacksonville, Jacksonville, Florida, December 3, 1999.
9. Invited Speaker – “Neurodevelopmental Outcomes of NICU Infants”. The Third Annual Symposium for Neonatal Professionals, Florida Yacht Club, Jacksonville, Florida – May 21, 1999.
10. Invited Speaker – “The Face of Infant Mortality”, Northeast Florida Healthy Start Coalition Chart Documentation Course, Jacksonville University, Jacksonville, Florida, June 6, 2001.
11. Invited Speaker - “Persistent Pulmonary Hypertension of the Neonate”, Fifth Annual First Coast Symposium for Neonatal Care Professionals, Florida Yacht Club, Jacksonville, Florida, May 3–5, 2001.
12. Invited Speaker – “Prevention and Treatment of Respiratory Distress Syndrome”, Fifth Annual First Coast Symposium for Neonatal Care Professionals, Florida Yacht Club, Jacksonville, Florida, May 3–5, 2001.
13. Invited Speaker – “A Few Clinical Observations on Outcomes Research”, University of Florida Jacksonville Research Day, LRC Auditorium, April 9, 2003.
14. Invited Speaker - “Risk Factors for Hyperbilirubinemia in the Newborn Infant”, Pediatric Grand Rounds at Baptist Medical Center, Jacksonville, Florida, November 17, 2004.
15. Invited Speaker – “Pediatrics For the Primary Care Physician”, Pediatric Conference at Amelia Island, Florida, Sponsored by The Nemours Foundation, June 10, 2004.
16. Invited Speaker – “Neonatal Diseases in the ECMO Unit”, ECMO Conference at Wolfson Children’s Hospital, Jacksonville, Florida, September 25, 2007.

REVIEWER:

2006 – present	Critical Care Medicine
2003 – present	Journal of Perinatology
1990 - present	Pediatrics
1991 - present	American Journal of Physiology (Heart Circ. Physiol.)
1993 - present	Pediatric Research
1994 - present	American Review of Respiratory Disease
1994 - present	Archives of Pediatrics & Adolescent Medicine
1998 - present	Journal of Pediatrics

Revised: 11/24/2008